RT Journal Article
SR Electronic
T1 A Label-free Optical Biosensor-Based Point-of-Care Test for the Rapid Detection of Monkeypox Virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309903
DO 10.1101/2024.07.03.24309903
A1 Aslan, Mete
A1 Seymour, Elif
A1 Brickner, Howard
A1 Clark, Alex E.
A1 Celebi, Iris
A1 Townsend, Michael B.
A1 Satheshkumar, Panayampalli S.
A1 Riley, Megan
A1 Carlin, Aaron F.
A1 Ünlü, M. Selim
A1 Ray, Partha
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309903.abstract
AB Diagnostic approaches that combine the high sensitivity and specificity of laboratory-based digital detection with the ease of use and affordability of point-of-care (POC) technologies could revolutionize disease diagnostics. This is especially true in infectious disease diagnostics, where rapid and accurate pathogen detection is critical to curbing the spread of disease. We have pioneered an innovative label-free digital detection platform that utilizes Interferometric Reflectance Imaging Sensor (IRIS) technology. IRIS leverages light interference from an optically transparent thin film, eliminating the need for complex optical resonances to enhance the signal by harnessing light interference and the power of signal averaging in shot-noise-limited operation to achieve virtually unlimited sensitivity. In our latest work, we have further improved our previous ‘Single-Particle’ IRIS (SP-IRIS) technology by allowing the construction of the optical signature of target nanoparticles (whole virus) from a single image. This new platform, ‘Pixel-Diversity’ IRIS (PD-IRIS), eliminated the need for z-scan acquisition, required in SP-IRIS, a time-consuming and expensive process, and made our technology more applicable to POC settings. Using PD-IRIS, we quantitatively detected the Monkeypox virus (MPXV), the etiological agent for Monkeypox (Mpox) infection. MPXV was captured by anti-A29 monoclonal antibody (mAb 69-126-3) on Protein G spots on the sensor chips and were detected at a limit-of-detection (LOD) - of 200 PFU/ml (∼3.3 attomolar). PD-IRIS was superior to the laboratory-based ELISA (LOD - 1800 PFU/mL) used as a comparator. The specificity of PD-IRIS in MPXV detection was demonstrated using Herpes simplex virus, type 1 (HSV-1), and Cowpox virus (CPXV). This work establishes the effectiveness of PD-IRIS and opens possibilities for its advancement in clinical diagnostics of Mpox at POC. Moreover, PD-IRIS is a modular technology that can be adapted for the multiplex detection of pathogens for which high-affinity ligands are available that can bind their surface antigens to capture them on the sensor surface.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was partially funded by UCSD Pandemic Response to Emerging Pathogens, Antimicrobial Resistance and Equity (PREPARE) Grant#: 2P30AI036214-29 (PR) and the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program (P30 AI036214) supported by the following NIH Institutes and Centers: NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIMH, NIMHD, NINR, FIC, and OAR. (M.S.U) received the National Science Foundation, NSF-TT PFI (2329817) award, which partially funded the research work presented in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MPXV and HSV-I were isolated from consented patient samples under UC San Diego IRB #160524.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors